Share Prices & Company Research

Market News

13 Jan 2021 | 22:42

Johnson and Johnson's Covid-19 vaccine generates 'promising' immune response

(Sharecast News) - Johnson&Johnson's Covid-19 vaccine generated a 'promising' immune response, results from from phase one and two clinical trials showed. Most of the volunteers taking part in the trials showed detectable neutralising antibodies 28 days after being administered the shot.

By day 57 all volunteers, with ages ranging from 18 to those 65 or older, had detectable antibodies, regardless of whether they were given a low or high dose of the vaccine.

Among those aged 18 to 55, the level of antibodies had remained stable for at least 71 days.

The data, which was published in the New England Journal of Medicine, also showed that the vaccine was safe.

In remarks to CNBC, J&J's Chief Scientific Officer, Paul Stoffels, said the readings from the trial gave his company "confidence" that the vaccine would prove highly effective in countering the virus.

According to CNBC, results from the ongoing 45,000-person phase three trial were expected later in January.

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 15th January 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.